China’s National Medical Products Administration has approved Eli Lilly’s oral weight-loss drug. $LLYB rose 3% premarket to a record high, while $NVO followed with a 1% gain.
This is China’s first approved oral GLP-1 weight-loss drug. China is the world’s second-largest pharmaceutical market, and its population with obesity ranks among the largest globally, with 500 million overweight or obese adults.
This is a huge opportunity! It’s expected to generate $1 billion–$14 billion in annual revenue.
This is China’s first approved oral GLP-1 weight-loss drug. China is the world’s second-largest pharmaceutical market, and its population with obesity ranks among the largest globally, with 500 million overweight or obese adults.
This is a huge opportunity! It’s expected to generate $1 billion–$14 billion in annual revenue.